© 2021 MJH Life Sciences and Cancer Network. All rights reserved.
© 2021 MJH Life Sciences™ and Cancer Network. All rights reserved.
December 05, 2020
Treatment with momelotinib improved overall survival and sustained efficacy outcomes in patients with intermediate- or high-risk myelofibrosis.
September 21, 2020
Based on these data, researchers indicated that adjuvant osimertinib would be an effective and practice-changing treatment in this setting.
May 29, 2020
Women who present with a new diagnosis of breast cancer already in stage IV should not be offered surgery and radiation for the primary breast tumor with the expectation of a survival benefit, according to results from the ECOG-ACRIN E2108 trial.